378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies
Vincent de Weger,
Martijn P. Lolkema,
Mark A. Dickson,
Axel Le Cesne,
Andrew J. Wagner,
M. Merqui-Roelvink,
Andréa Varga,
W. Tap,
Gerri E. Schwartz,
George D. Demetri,
European Journal of Cancer · 2014 · 10 citations · 0 references